Skip to content

High-concentration Small-volume Versus Low-concentration Large-volume Iodine Solution for Esophageal Chromoendoscopy

High-concentration Small-volume Versus Low-concentration Large-volume Iodine Solution for Esophageal Chromoendoscopy: a Multicenter, Randomized Equivalence Trial

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06063941
Enrollment
450
Registered
2023-10-03
Start date
2023-10-10
Completion date
2024-04-30
Last updated
2024-08-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Esophageal Squamous Cell Carcinoma

Keywords

Lugol chromoendoscopy, Adverse event

Brief summary

This clinical trial aims to test the participants' tolerance for different concentration iodine solutions during esophageal chromoendoscopy. The main question it aims to answer is: Under the same iodine dosage, do the participants have the same tolerance for 1% and 5% iodine solutions? Participants will be asked to score based on pain and discomfort and describe symptoms and corresponding location at 5 minutes (only for unanesthetized participants) and 30 minutes after chromoendoscopy.

Detailed description

Lugol's iodine chromoendoscopy is the commonly used method for detecting and diagnosing esophageal squamous cell carcinoma. However, iodine can induce mucosal irritation and has been commonly associated with adverse retrosternal symptoms, including retrosternal pain and/or heartburn. The existing research shows that spraying iodine solution neutralizers (Sodium thiosulfate solution, N-acetylcysteine, and vitamin C solution) after esophageal iodine chromoendoscopy can alleviate patient discomfort. However, a recent study has shown that excessive iodine concentration or excessive dosage of iodine can still increase patient discomfort even under spraying an iodine solution neutralizer. It is currently unclear whether the factors affecting patient tolerance are the iodine solution concentration or the total dosage of iodine used. Therefore, the multicenter randomized controlled trial will compare the patient's tolerance for the 1% and 5% iodine solutions under the same iodine dosage conditions. The trial will help determine the specific reasons influencing patient tolerance. Participants will be asked to score based on pain and discomfort and describe symptoms and corresponding location at 5 minutes (only for unanesthetized participants) and 30 minutes after chromoendoscopy.

Interventions

DRUG1% Lugol's iodine solution

1% Lugol iodine solution was sprayed from the esophagogastric junction towards a location approximately 20 cm away from the upper incisors in the cervical esophagus.

DRUG5% Lugol's iodine solution

Before chromoendoscopy, a 20 ml syringe was employed to draw 3 ml of 5% iodine stock solution and 17 ml air. When staining, the iodine was quickly expelled through the endoscope's working channel at 20 cm of the esophagus from the incisor. An iodine mist was created because of the rapid spurt of the iodine solution and air, which prompts even distribution of the iodine solution on the esophageal wall. The lower segments of the esophageal wall were stained with the remaining iodine solution in the working channel by repeatedly spraying the air/iodine mixture using the syringe, resulting in consistent and uniform staining for the whole esophagus.

Sponsors

Ankang Central Hospital
CollaboratorOTHER
The First Affiliated Hospital of ShiheziI University
CollaboratorUNKNOWN
Xi'an International Medical Center Hospital
CollaboratorOTHER
Air Force 986 Hospital
CollaboratorUNKNOWN
Xijing Hospital of Digestive Diseases
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Patients undergoing esophageal Lugol's iodine chromoendoscopy. * Age ≥ 18

Exclusion criteria

* Patients allergic to iodine or with hyperthyroidism; * Patients with esophageal varices, esophageal ulcer or other conditions inadvisable for Lugol chromoendoscopy; * Patients with severe gastroesophageal reflux disease or reflux symptoms which may interfered with the outcome measures of current study; * Patients with postoperative esophageal stenosis affecting endoscopic observation; * Patients who could not cooperate with the observation and data collection including patients with mental disorders, severe neurosis, dysgnosia or communication disorder; * Patients with advanced-stage tumors; * Patients after upper gastrointestinal surgery; * Patients who do not agree to sign informed consent forms or follow the trial requirement.

Design outcomes

Primary

MeasureTime frameDescription
Visual analogue scale scores at 30 minutes after chromoendoscopy30 minute after endoscopyAccording to the visual analogue scale, participants will be asked to score based on pain or discomfort 30 minutes after chromoendoscopy.

Secondary

MeasureTime frameDescription
The color subjective evaluation after chromoendoscopyDuring endoscopy.The endoscopist will be asked to complete a questionnaire survey immediately after chromoendoscopy. The questionnaire asked the endoscopist to rate the staining effect as good (The color concentration is sufficient and the color retention time is adequate) or poor (The color concentration is insufficient and/or the color retention time is inadequate).
Heart rate variability5 minute or 30 minute after endoscopyThe percentage of heart rate change 5 min (only for unanesthetized participants) or 30 min compared to that before endoscopy.
The incidence rate of the need for additional iodine solution sprayingDuring endoscopy.When the endoscopist believes that insufficient esophageal iodine staining affects the detection or diagnosis of lesions, they can spray additional iodine solution. The incidence rate of the need for additional iodine solution spraying of the two groups will be compared.
The dosage of additional iodine sprayingDuring endoscopyWhen the endoscopist believes that insufficient esophageal iodine staining affects the detection or diagnosis of lesions, they can spray additional iodine solution. The dosage of additional iodine spraying of the two groups will be compared.
The color objective evaluation after chromoendoscopy2-3 minutes after spraying Lugol's iodine.After spraying Lugol's iodine, the esophageal mucosa displaying a homogeneous dark brown staining was classified as normal, while faded or unstained lesions larger than 0.5 cm were deemed potential high-grade intraepithelial neoplasia or mucosal cancer. The Lugol's unstained lesions were further evaluated for the presence of the pink-color sign and photographed 2-3 minutes after Lugol's iodine staining. The images were also taken at 30 cm distal to the incisors at 2-3 minutes after Lugol's iodine staining if no lesion was found. The images were retrospectively analyzed and scored for an objective evaluation based on the L\* a\* b\* (L\* = light/dark; a\* = red/green; b\* = yellow/blue) color values in the CIELAB color space system.
The incidence rate of esophageal spasmsDuring endoscopyThe incidence rate of esophageal spasms of the two groups will be compared.
The incidence rate of adverse incidentsUp to 48 hours after the endoscopyThe incidence rate of adverse incidents of the two groups will be compared.
The incidence rate of upper abdominal discomfort or pain.5 minute or 30 minute after endoscopyParticipants will be asked to describe retrosternal discomfort symptoms and corresponding location at 5 minutes (only for unanesthetized participants)) and 30 minutes after chromoendoscopy. The incidence rate of upper abdominal discomfort or pain will be compared between the two groups.
Associated factors for visual analogue scale scoresUp to 48 hours after the endoscopyVisual analogue scale scores may be influenced by other factors. Univariable analysis will first be used to identify potential factors that influenced visual analogue scale scores. All possible factors will then be included in multivariable analysis.
Visual analogue scale scores at 5 minutes after chromoendoscopy5 minute after endoscopyAccording to the visual analogue scale, participants without sedation or general anesthesia will be asked to score based on pain or discomfort 5 minutes after chromoendoscopy.

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026